B7-33 is a single-chain peptide based on the B-chain of human gene-2 (H2) relaxin, developed by a group at the Florey Institute of Neuroscience and Mental Health, University of Melbourne.1 The app files it as a relaxin analog in the healing peptide category and grades its evidence as emerging. The app's notes describe it as preclinical only, with no human trials and no established human dose. Hossain and colleagues described it in Chemical Science in 2016, and the authors state that "B7-33 represents the first functionally selective agonist of the complex GPCR, RXFP1".2 The studies read for this compound are in mice, rats, cultured cells and human serum; no study in people was identified.2,3,4,5,6,7

H2 relaxin acts at the receptor RXFP1, and its signalling includes cyclic adenosine monophosphate (cAMP) and extracellular-signal-regulated kinases (ERK)1/2.2 Hossain and colleagues report that B7-33 binds RXFP1 and "preferentially activate the pERK pathway over cAMP in cells that endogenously expressed RXFP1".2 Praveen and colleagues describe the same pattern in fibroblasts: B7-33 "barely activate cyclic adenosine monophosphate (cAMP)" while it "activated the pERK pathway with a potency similar to H2 relaxin".1 The same group notes that the signalling "seemed to be cell-specific".1 In cells engineered to express RXFP1 (HEK-293T), the 2016 paper reports that B7-33 had "modest to poor affinity and potency", and that B7-33 "poorly induced pERK1/2 phosphorylation" there.2 The authors write that B7-33 "did not activate cAMP activity in HEK-RXFP2 cells", a different relaxin-family receptor.2 For the anti-fibrotic action, the authors state that the "molecular mechanism" involved "its activation of RXFP1-angiotensin II type 2 receptor heterodimers that induced selective downstream signaling of pERK1/2 and the collagen-degrading enzyme, matrix metalloproteinase (MMP)-2".2 The experiment behind this was in cultured rat renal myofibroblasts, where an angiotensin II type 2 receptor antagonist blocked the MMP-2-promoting effect of B7-33.2 In isolated mouse cardiomyocytes, Devarakonda and colleagues report that B7-33 at 50 and 100 nmol/L "improved cell survival and reduced the expression of GRP78", described as an endoplasmic reticulum stress marker.3 In solution the peptide is described as "an unstructured single-chain peptide" and, by NMR, "mainly unstructured in solution".1,2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.3 h
Bioavailability
95%
Typical dose
100–400 mcg/day
Route
SubQ
Time to peak
~0.3 h

The app lists a half-life of 0.3 hours, a time to peak of 0.3 hours, a bioavailability of 95% and a duration of 6 hours, in a one-compartment model with subcutaneous dosing. The sources read report a different figure for the half-life and none of the other three.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~0.3 h (18 min)About 6 minutes in human serum in vitro (n = 3 experiments); in vivo half-life of H2 relaxin is approximately ten minutes1
Bioavailability95%No figure for B7-33; the 2020 mouse study's authors "were unable to quantify the bioavailability" of the injected peptide3
Time to peak~0.3 hNone reported in the sources read
Duration6 hNone reported in the sources read

Praveen and colleagues (International Journal of Molecular Sciences, 2023) added B7-33 to human serum and followed the peptide by HPLC over 480 minutes.1 They state: "The in vitro half-life of B7-33 and AcK(PalmGlu)-PEG12-B7-33 is 6 and 60 min, respectively", the second being a palmitic acid-conjugated analogue.1 They also write that B7-33's "in vivo half-life is expected to be even less than H2 relaxin", and that the lipidated molecule "needs to be investigated in in vivo animal models".1 The app's 0.3 hours (18 minutes) is therefore about three times the in vitro serum figure of 6 minutes, and the sources read give no measured half-life of B7-33 in a living animal or a person.1 In the 2020 mouse infarct study the authors write that B7-33 "is likely to possess similar half" life to relaxin, an inference rather than a measurement.3

4

Human studies and preclinical evidence

No controlled trial or other study in people was identified in PubMed or ClinicalTrials.gov. The table lists the preclinical studies read. Every row is a study in cells, animals or serum, and none can be read as a result in people.

Table 4.1Human studies and preclinical evidence7 rows
Study and yearDesignPeopleDose and lengthMain result
Hossain and colleagues, Chem Sci 20162Cell assays and three rodent models against saline and H2 relaxin; NHMRC-fundedNone: rats and miceRat heart 0.5 mg/kg/day for 28 days; mouse heart 0.25 mg/kg/day for 14 days; mouse lung 0.25 mg/kg/day for 14 daysLower collagen than injured controls in all three models; airway reactivity stayed above saline controls; no prostate tumor growth beyond controls
Praveen and colleagues, Int J Mol Sci 20231Human serum stability assay and fibroblast assay; NHMRC-fundedNone: serum and human dermal fibroblastsB7-33 100 ng/mL on cells for up to 14 daysSerum half-life about 6 min; effect on myofibroblast marker faded after 5 to 14 days
Devarakonda and colleagues, J Am Heart Assoc 20203Mouse ischemia-reperfusion against saline; NIH and AHA fundedNone: adult male CD1 mice0.25 mg/kg at reperfusion; 0.25 mg/kg twice daily in a 7-day groupInfarct size 21.99% versus 45.32% (P=0.02); fractional shortening 29% versus 23% (P=0.02)
Alam and colleagues, Biomed Pharmacother 20234Mouse isoprenaline cardiomyopathy against relaxin (RLX) and perindoprilNone: adult male 129sv miceB7-33 0.25 mg/kg/day s.c., days 7 to 14Reduced left ventricular fibrosis like RLX; perindopril did not reduce fibrosis
Marshall and colleagues, Eur J Pharmacol 20175Rat bolus against placebo and serelaxin; mouse artery ex vivoNone: male Wistar rats; female mouse arteriesB7-33 13.3 μg/kg tail vein; 15 and 30 nM ex vivoEnhanced bradykinin-mediated relaxation in mesenteric artery; no overall effect in renal artery or aorta
Welch and colleagues, ACS Appl Mater Interfaces 20196PLGA-coated implants releasing B7-33 in mice against no peptide; controlled release shown in vitroNone: miceSubcutaneous implantation over a 6 week period; dose not given in the record readCapsule thickness reduced by 49.2%
Somanader-Livera and colleagues, J Biomed Sci 20257Mouse cardiomyopathy, nanoparticle-conjugated B7-33 against perindopril and unconjugated peptideNone: miceSPION-B7-33 25 ng/day by oral gavage every 72 h, days 14 to 42Conjugate beat perindopril on fibrosis; oral peptide alone did not keep the effect

Deeper analysis: Hossain and colleagues, Chemical Science, 2016

The paper reports the design of B7-33, its binding and signalling in cells, and its effects in three rodent models.2 In adult male Sprague-Dawley rats, 8 weeks after a heart attack was induced, B7-33 or H2 relaxin (each at 0.5 mg/kg/day) was given by intraperitoneal osmotic mini-pump for 28 days, and both reduced left ventricular collagen against saline.2 The authors write that the results "suggesting that treatment with B7-33 was as effective as H2 relaxin for improving LV function in the MI-induced rat model of heart failure", based on lower left ventricular end-diastolic pressure.2 In male 129SV mice given isoprenaline for 5 days (n = 7–8 per subgroup), B7-33 (0.25 mg/kg/day, corrected for molecular weight) by subcutaneous minipump lowered interstitial collagen staining by about 51%, against about 57% for H2 relaxin at 0.5 mg/kg/day.2 The authors add that these collagen effects "were independent of their ability to regulate systolic blood pressure".2 In female Balb/c mice with ovalbumin-induced chronic allergic airways disease, B7-33 was given intranasally once daily at 0.25 mg/kg/day for 14 days; it "totally reversed the increased epithelial thickness".2 The secondary result is less complete: airway hyperresponsiveness was "partially but significantly reversed", and reactivity "remained significantly higher" than in saline-treated controls.2 In a mouse prostate cancer model, H2 relaxin at 0.15 mg/kg/day increased prostate size by more than 150%, while B7-33 at 0.075 or 0.25 mg/kg/day "failed to exacerbate mouse prostate tumor size".2 Limitations the paper itself states or implies: B7-33 "poorly induced pERK1/2 phosphorylation" in the engineered HEK-RXFP1 cells, and the authors call it "an attractive lead for further modification to improve stability, potency and in vivo efficacy".2 Funding came from Australian grants: the paper states "This work was supported by National Health & Medical Research Council (NHMRC) of Australia Grants", with fellowships and scholarships to several authors.2 The text read carries no commercial sponsor.

Deeper analysis: Devarakonda and colleagues, Journal of the American Heart Association, 2020

The group at Virginia Commonwealth University, with two authors from the Florey Institute (Praveen and Hossain), gave B7-33 to adult male CD1 mice at the start of reperfusion after 30 minutes of coronary ligation, with saline as comparator.3 The authors report that B7-33 "significantly reduced infarct size (21.99% versus 45.32%; P=0.02) and preserved fractional shortening (29% versus 23%; P=0.02) compared with vehicle".3 At 7 days the fractional shortening difference "further increased" (29% versus 20% for the B7-33 and vehicle groups).3 Not every measure differed: the text states that "Area at risk did not differ significantly between the groups", and the figure legend reports "No significant differences in LVID at diastole among the experimental groups" at 24 hours.3 The authors write that they "were unable to quantify the bioavailability" after injection because the relaxin-2 ELISA kit "failed to recognize" B7-33 in preliminary work.3 Their stated limitations: results "are limited by the nature of our animal model", "The exclusive use of male mice limits the scope of this current work", and testing in people "necessitates extensive safety and efficacy trials in humans".3 Funding was from the American Heart Association, the Wright Center for Clinical and Translational Research, the Australian National Health and Medical Research Council (to Hossain, an author) and the US National Institutes of Health.3 The paper's Disclosures section reads "None."3

Deeper analysis: Praveen and colleagues, International Journal of Molecular Sciences, 2023

This laboratory study measured how long B7-33 lasts in human serum and tested fatty-acid conjugated analogues.1 Serum stability studies (n = 3) gave an in vitro half-life of 6 minutes for B7-33 and 60 minutes for the analogue AcK(PalmGlu)-PEG12-B7-33.1 In human dermal fibroblasts stimulated with TGF-β1, B7-33 at 100 ng/mL suppressed the myofibroblast marker α-SMA at 72 hours, but levels "fully returned" to those of stimulated cells after 5 to 14 days in culture.1 The authors state that the lead analogue "will be studied in animal models to measure its PK/PD properties", so the in vivo behaviour of B7-33 itself was not reported there.1 Funding was from the National Health and Medical Research Council (grants GNT2001178, GNT2001027, GNT1135837), and the authors "declare no conflict of interest".1

Other preclinical reports

Alam and colleagues (Biomedicine and Pharmacotherapy, 2023) gave isoprenaline-injured mice B7-33 at 0.25 mg/kg/day, relaxin at 0.5 mg/kg/day or perindopril at 1 mg/kg/day subcutaneously from days 7 to 14.4 They report that "Both B7-33 and RLX equivalently reduced LV fibrosis", while perindopril lowered blood pressure and inflammation "but not fibrosis or hypertrophy"; the authors declare no conflict of interest, and the record read gives no funding statement.4 Marshall and colleagues (European Journal of Pharmacology, 2017) gave male Wistar rats a tail vein injection of B7-33 (13.3 μg/kg) and tested arteries three hours later.5 B7-33 "selectively enhanced bradykinin-mediated endothelium-dependent relaxation" in the mesenteric artery but "had no overall effects on relaxation in the small renal artery or aorta".5 In virgin female mouse mesenteric arteries pre-incubated in placental trophoblast conditioned media, co-incubation with B7-33 or serelaxin (15, 30nM) "prevented the development of endothelial dysfunction", an ex vivo result.5 Welch and colleagues (ACS Applied Materials and Interfaces, 2019) released B7-33 from a PLGA coating on implants and report a reduction in capsule thickness of 49.2% over 6 weeks in mice.6 The records read for the Welch and Marshall studies give no funding or competing-interest statement.6,5 Somanader-Livera and colleagues (Journal of Biomedical Science, 2025) conjugated B7-33 to iron oxide nanoparticles (SPION) and report greater anti-fibrotic efficacy than perindopril when given orally every 72 hours for 4 weeks, with the effect "not maintained" by orally administered B7-33 alone.7 The authors state that "The clinical translation of these findings will require scalable, GMP-compliant nanoparticle synthesis and careful assessment of long-term safety"; funding was from Monash University and a UK fellowship and Asthma Lung UK grant, and the authors "declare no competing interests".7

5

Doses reported in studies and on labels

No label for B7-33 was identified in DailyMed, and the sources read report no human dose. The app lists 100 to 400 mcg/day; the studies below used animal doses per kilogram, so the two cannot be compared directly.

Table 5.1Doses reported in studies and on labels8 rows
StudyModel and comparatorDose, route and scheduleDuration and n
Hossain 20162Rat after myocardial infarction; saline and H2 relaxinB7-33 0.5 mg/kg/day, intraperitoneal osmotic mini-pump28 days; n not stated in the text
Hossain 20162Mouse isoprenaline model; H2 relaxin 0.5 mg/kg/dayB7-33 0.25 mg/kg/day, subcutaneous osmotic minipumpDays 1 to 14; n = 7–8 per subgroup
Hossain 20162Mouse allergic airways model; H2 relaxin 0.5 mg/kg/dayB7-33 0.25 mg/kg/day, intranasal, once daily14 days; n = 11–15 mice per group
Hossain 20162Mouse prostate tumor model; H2 relaxin 0.15 mg/kg/dayB7-33 0.075 and 0.25 mg/kg/dayFrom days 2 to 10 after tumor cell injection; n not stated in the text
Devarakonda 20203Mouse ischemia-reperfusion; salineB7-33 0.25 mg/kg intraperitoneal at reperfusion; 0.25 mg/kg per dose twice daily in the 7-day group24 hours or 7 days; n = 7 (B7-33) and 8 (vehicle) for infarct size, n = 14–18 for the vehicle and B7-33 groups for echocardiography at 24 hours
Alam 20234Mouse isoprenaline cardiomyopathy; RLX 0.5 mg/kg/day and perindopril 1 mg/kg/dayB7-33 0.25 mg/kg/day subcutaneousDays 7 to 14 after injury; n not stated in the record read
Marshall 20175Male Wistar rats; placebo and serelaxin 26.6 μg/kgB7-33 13.3 μg/kg, single tail vein injectionVessels tested 3 hours later; n not stated in the record read
Somanader-Livera 20257Mouse isoprenaline cardiomyopathy; perindopril 60 ng/day, unconjugated peptide, empty nanoparticlesSPION-B7-33 25 ng/day by oral gavage every 72 hDays 14 to 42 after injury; n = 6 to 7 per group in the figure legend
6

Side effects reported

No adverse-event rates in people were found in the sources read, and no study in people was identified. One safety-type result for B7-33 in the studies read is the 2016 mouse prostate tumor model, in which H2 relaxin increased prostate size and B7-33 "failed to exacerbate mouse prostate tumor size".2 In that model RM1 prostate cancer cells were implanted in mice, a significant tumor developed after 10 days, and B7-33 was given from days 2 to 10.2 A 6-week safety study in the 2025 mouse paper gave glycinated empty nanoparticles, without B7-33, to healthy mice every 72 hours; the authors report it "did not affect animal mortality", with "Only mild to moderate vacuolar changes and immune cell influx" in the liver of untreated and treated mice.7

7

Bloodwork and markers

The app lists no health markers to monitor for B7-33. In the animal studies the outcomes were measured in tissue and by echocardiography, for example collagen staining, infarct size and fractional shortening, rather than in routine blood tests.2,3

8

Regulatory and anti-doping status

No label for B7-33 was identified in DailyMed, and the studies read are laboratory and animal work. The 2026 WADA Prohibited List text contains no entry naming B7-33 or relaxin.8 Section S0 covers "Any pharmacological substance which is not addressed by any of the subsequent sections" with no approval for human therapeutic use, such as "drugs under pre-clinical or clinical development", and the list does not say whether B7-33 falls within it.8 Section S2.3 on growth factors and growth factor modulators lists named factors such as FGFs, HGF, IGF-1, MGFs, PDGF, thymosin-beta-4 and VEGF, and does not name relaxin.8

The sources read do not report a human dose, a human trial or an adverse-event rate in people. The in vivo half-life, time to peak and bioavailability of B7-33 itself were not reported in the sources read; the only half-life is the in vitro serum figure of about 6 minutes.1,3 Female animals were not used in the 2020 mouse infarct study, and the authors write that analysis "in both male and female animal populations would be necessary".3 Whether the signalling bias seen in cultured fibroblasts holds in other tissues is open: the 2016 paper reports weak pERK activation in engineered HEK cells, and Praveen and colleagues note the signalling "seemed to be cell-specific".2,1

What is the half-life of B7-33?

The only half-life measured in the sources read is an in vitro figure of about 6 minutes in human serum, and the app lists 0.3 hours (18 minutes).1 The same authors write that the in vivo half-life "is expected to be even less than H2 relaxin", which they put at approximately ten minutes.1

What is B7-33?

B7-33 is a single-chain peptide based on the B-chain of human gene-2 relaxin.1 The app classes it as a relaxin analog.

Has B7-33 been tested in people?

No study in people was identified in PubMed or ClinicalTrials.gov. The app's notes also describe it as preclinical only.

Is B7-33 approved by the FDA?

No label for B7-33 was identified in DailyMed.

Is B7-33 banned by WADA?

The 2026 WADA Prohibited List text does not name B7-33 or relaxin.8 Section S0 of the list covers substances under pre-clinical or clinical development that have no approval for human therapeutic use, and the list does not state whether B7-33 falls within it.8

Which receptor does B7-33 act on?

B7-33 binds the relaxin receptor RXFP1.2 In cells it favoured pERK signalling over cAMP, and in HEK-293T cells engineered to express RXFP1 the authors report modest to poor affinity and potency.2

Did B7-33 promote tumor growth in animals?

In a mouse prostate tumor model over 10 days, B7-33 at 0.075 and 0.25 mg/kg/day "failed to exacerbate mouse prostate tumor size", while H2 relaxin increased prostate size by more than 150%.2

What did B7-33 do to heart fibrosis in animals?

In rats and mice, Hossain and colleagues report lower left ventricular collagen with B7-33 than with saline in injury models, with results similar to H2 relaxin.2 These are animal results and are not results in people.2

12

References

  1. Praveen P, Wang C, Handley TNG, et al. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity. Int J Mol Sci 2023. PMID 37047588
  2. Hossain MA, Kocan M, Yao ST, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chem Sci 2016. PMID 30155023
  3. Devarakonda T, Mauro AG, Guzman G, et al. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. J Am Heart Assoc 2020. PMID 32295457
  4. Alam F, Gaspari TA, Kemp-Harper BK, et al. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother 2023. PMID 36753958
  5. Marshall SA, O'Sullivan K, Ng HH, et al. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). Eur J Pharmacol 2017. PMID 28478069
  6. Welch NG, Mukherjee S, Hossain MA, et al. Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation. ACS Appl Mater Interfaces 2019. PMID 31713411
  7. Somanader-Livera DVN, Wei C, Wang C, et al. Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration. J Biomed Sci 2025. PMID 41382190
  8. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list